Clinical trials: Menopause-Hot Flashes
- Condition Menopause-Hot Flashes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General…
- Trial name
- NCT04209543
- Testing
- Estetrol, Progesterone
- Where
- 224 sites in United States, Argentina and 12 more
- Volunteers
- 1,570 people, healthy volunteers welcome
- Sponsor
- Estetra
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.
- Trial name
- E4Comfort II (NCT04090957)
- Testing
- Estetrol oral tablet
- Where
- 117 sites in United States, Canada
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Estetra
Hot Flushes
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
- Trial name
- NCT02834312
- Testing
- Estetrol
- Where
- Belgium
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
Hot Flashes, Fatty Acids
Hot Flashes and Omega 3
The main objective is to evaluate the effects of omega-3 fatty acids on hot flashes frequency.
- Conditions
- Hot Flashes, Fatty Acids, Menopause
- Trial name
- BOOM3 (NCT02062528)
- Testing
- omega-3 fatty acids
- Where
- France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Vivatech
Hot Flushes, Vasomotor Symptoms
A Study of MF101 in Postmenopausal Women
This phase 3a study is designed to assess the safety and efficacy of MF101 on the frequency of moderate to severe hot flushes in postmenopausal women.
- Trial name
- HERBA (NCT00906308)
- Testing
- MF101 5 g/day, MF101 10 g/day
- Where
- 50 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Bionovo
Menopause, Hot Flashes
The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women
The objective of this study is to evaluate the safety and efficacy of extended-release oxybutynin chloride for the treatment of vasomotor symptoms, also known as hot flashes, in healthy naturally postmenopausal women.
- Trial name
- NCT00990886
- Testing
- Oxybutynin chloride
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Joint Discomfort, Joint Pain, Stiffness, Function
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70.
- Conditions
- Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes
- Trial name
- NCT07238478
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Bonafide Health
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Hot Flashes
A Clinical Trial Assessing Safety of MF101 for Hot Flushes
This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks.
- Trial name
- NCT01300078
- Testing
- MF101
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bionovo
Vasomotor Symptoms
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
- Trial name
- NCT00683800
- Testing
- desvenlafaxine succinate (DVS) SR
- Where
- 121 sites in United States, Canada
- Volunteers
- 2,186 people, healthy volunteers welcome
- Sponsor
- Pfizer
Menopausal Symptoms
A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women
The purpose of this study is to assess the effectiveness of an herbal combination product called Nu Femme, on menopausal symptoms in peri-menopausal women.
- Trial name
- 14NMHB (NCT02269891)
- Testing
- Nu Femme
- Where
- 4 sites in Canada
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Hot Flashes
Safety and Efficacy of Dr. Tagliaferri's Menopause Formula
The primary goal of this study is to evaluate the safety and efficacy of 12 weeks of treatment of 4 grams/day of Dr. Tagliaferri's Menopause Formula (administered as 2 grams PO BID) in reducing the frequency of menopausal…
- Trial name
- NCT01957306
- Testing
- Dr. Tagliaferri's Menopause Formula
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Herba Buena, Inc
Postmenopausal Osteoporosis, Postmenopause
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™.
- Trial name
- NCT00381251
- Testing
- Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes
The researchers propose a Phase II randomized, double-blind, placebo-controlled trial of 180 healthy postmenopausal women experiencing at least 5 hot flashes per day or 35 hot flashes per week.
- Trial name
- NCT00119665
- Testing
- MF101
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Bionovo